Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1972 1
1977 1
1978 1
1980 1
1981 1
1982 2
1984 2
1985 2
1986 2
1987 2
1988 7
1989 3
1990 2
1991 3
1992 6
1993 9
1994 4
1995 10
1996 9
1997 18
1998 20
1999 19
2000 17
2001 34
2002 37
2003 36
2004 63
2005 75
2006 89
2007 114
2008 141
2009 210
2010 240
2011 274
2012 360
2013 389
2014 463
2015 558
2016 599
2017 649
2018 707
2019 846
2020 860
2021 1071
2022 1070
2023 1002
2024 441

Text availability

Article attribute

Article type

Publication date

Search Results

9,022 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73.1 [95% CI -8.6 to 154.8]; autoimmune ILDs 104.0 [21.1 to 186.9]; idiop …
The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD …
Subgroup discovery in non-inferiority trials.
Fazzari MJ, Kim MY. Fazzari MJ, et al. Stat Med. 2021 Oct 30;40(24):5174-5187. doi: 10.1002/sim.9118. Epub 2021 Jun 22. Stat Med. 2021. PMID: 34155676
Recent NI trials have performed a priori subgroup analyses using standard statistical tests for interaction, but there is increasing interest in more flexible machine learning approaches for post-hoc subgroup discovery. ...We considered the Virtual Twin method for t …
Recent NI trials have performed a priori subgroup analyses using standard statistical tests for interaction, but there is increasing …
Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
Fujihara K, Kim HJ, Saida T, Misu T, Nagano Y, Totsuka N, Iizuka M, Kido S, Terata R, Okumura K, Hirota S, Cree BAC. Fujihara K, et al. Mult Scler Relat Disord. 2023 Nov;79:104938. doi: 10.1016/j.msard.2023.104938. Epub 2023 Aug 20. Mult Scler Relat Disord. 2023. PMID: 37769428 Free article. Clinical Trial.
NMOSD attack rates were comparable between the Asian and non-Asian subgroups. In the Asian subgroup, the rates of Expanded Disability Status Scale worsening from baseline, active MRI lesions, and disease-related hospitalizations tended to be lower in the inebilizuma …
NMOSD attack rates were comparable between the Asian and non-Asian subgroups. In the Asian subgroup, the rates of Expanded Dis …
The Fontan Udenafil Exercise Longitudinal Trial: Subgroup Analysis.
Goldberg DJ, Hu C, Lubert AM, Rathod RH, Penny DJ, Petit CJ, Schumacher KR, Ginde S, Williams RV, Yoon JK, Kim GB, Nowlen TT, DiMaria MV, Frischhertz BP, Wagner JB, McHugh KE, McCrindle BW, Cartoski MJ, Detterich JA, Yetman AT, John AS, Richmond ME, Yung D, Payne RM, Mackie AS, Davis CK, Shahanavaz S, Hill KD, Almaguer M, Zak V, McBride MG, Goldstein BH, Pearson GD, Paridon SM; Pediatric Heart Network Investigators. Goldberg DJ, et al. Pediatr Cardiol. 2023 Dec;44(8):1691-1701. doi: 10.1007/s00246-023-03204-y. Epub 2023 Jun 29. Pediatr Cardiol. 2023. PMID: 37382636 Clinical Trial.
Differences among subgroups were evaluated using ANCOVA modeling with fixed factors for treatment arm and subgroup and the interaction between treatment arm and subgroup. Within-subgroup analyses demonstrated trends toward quantitative improvements in …
Differences among subgroups were evaluated using ANCOVA modeling with fixed factors for treatment arm and subgroup and the int …
Propensity score analysis for correlated subgroup effects.
Liu SY, Liu C, Nehus E, Macaluso M, Lu B, Kim MO. Liu SY, et al. Stat Methods Med Res. 2020 Apr;29(4):1067-1080. doi: 10.1177/0962280219850595. Epub 2019 May 30. Stat Methods Med Res. 2020. PMID: 31144601
Factors that define subgroups may be correlated, complicating evaluation of subgroup effects, especially in observational studies requiring control of confounding variables. ...Whereas jointly analyzing multiple identifiers provides estimates of the desired subgr …
Factors that define subgroups may be correlated, complicating evaluation of subgroup effects, especially in observational stud …
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Gelmon K, Walshe JM, Mahtani R, Joy AA, Karuturi M, Neven P, Lu DR, Kim S, Schnell P, Bananis E, Schwartzberg L. Gelmon K, et al. Breast. 2021 Oct;59:321-326. doi: 10.1016/j.breast.2021.07.017. Epub 2021 Jul 28. Breast. 2021. PMID: 34388698 Free PMC article. Clinical Trial.
Baseline characteristics were similar between subgroups and between each arm within subgroups. Regardless of baseline preexisting condition, palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole. Treatment-emergent AEs associated with palboci …
Baseline characteristics were similar between subgroups and between each arm within subgroups. Regardless of baseline preexist …
Evaluating sensitivity to classification uncertainty in latent subgroup effect analyses.
Loh WW, Kim JS. Loh WW, et al. BMC Med Res Methodol. 2022 Sep 24;22(1):247. doi: 10.1186/s12874-022-01720-8. BMC Med Res Methodol. 2022. PMID: 36153493 Free PMC article.
BACKGROUND: Increasing attention is being given to assessing treatment effect heterogeneity among individuals belonging to qualitatively different latent subgroups. Inference routinely proceeds by first partitioning the individuals into subgroups, then estimating th …
BACKGROUND: Increasing attention is being given to assessing treatment effect heterogeneity among individuals belonging to qualitatively dif …
Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK, Lee JY, Cheong H, Ramaswamy V, Park SH, Kool M, Phi JH, Choi SA, Cavalli F, Taylor MD, Kim SK. Park AK, et al. BMC Cancer. 2019 Jun 11;19(1):571. doi: 10.1186/s12885-019-5742-x. BMC Cancer. 2019. PMID: 31185958 Free PMC article.
BACKGROUND: Using a pathway-focused approach, we aimed to provide a subgroup-specific basis for finding novel therapeutic strategies and further refinement of the risk stratification in pediatric medulloblastoma. ...CONCLUSIONS: The results underscore several subgroup …
BACKGROUND: Using a pathway-focused approach, we aimed to provide a subgroup-specific basis for finding novel therapeutic strategies …
Iterative Causal Forest: A Novel Algorithm for Subgroup Identification.
Wang T, Keil AP, Kim S, Wyss R, Htoo PT, Funk MJ, Buse JB, Kosorok MR, Stürmer T. Wang T, et al. Am J Epidemiol. 2023 Nov 7:kwad219. doi: 10.1093/aje/kwad219. Online ahead of print. Am J Epidemiol. 2023. PMID: 37943684
Precisely and efficiently identifying subgroups with heterogeneous treatment effects (HTEs) in real-world evidence studies remains a challenge. Based on the causal forest (CF) method, we developed an iterative CF (iCF) algorithm to identify HTEs in subgroups defined …
Precisely and efficiently identifying subgroups with heterogeneous treatment effects (HTEs) in real-world evidence studies remains a …
Effect of Edoxaban Versus Antiplatelet Therapy on Leaflet Thrombosis and Cerebral Thromboembolism After TAVI According to Major Clinical and Anatomic Factors in Prespecified Subgroup Analysis from the ADAPT-TAVR Trial.
Lee JH, Ahn JM, Kang DY, Kim KW, Koo HJ, Yang DH, Jung SC, Kim B, Wong YTA, Lam CCS, Yin WH, Wei J, Lee YT, Kao HL, Lin MS, Ko TY, Kim WJ, Kang SH, Yun SC, Ko E, Park H, Lee SA, Kim DH, Park SJ, Park DW; ADAPT-TAVR Investigators. Lee JH, et al. Am J Cardiol. 2023 Sep 15;203:352-361. doi: 10.1016/j.amjcard.2023.06.018. Epub 2023 Jul 28. Am J Cardiol. 2023. PMID: 37517131 Clinical Trial.
Cox regression models assessed the consistency of the treatment effects in the prespecified subgroups. The favorable effect of edoxaban versus DAPT on the leaflet thrombosis was consistent across multiple clinical or anatomic subgroups, without significant interacti …
Cox regression models assessed the consistency of the treatment effects in the prespecified subgroups. The favorable effect of edoxab …
9,022 results